Evommune’s phase 2b flops, ending challenge to Novartis in hives
A phase 2b trial of Evommune’s EVO756 has missed its primary endpoint, wiping out a would-be rival to Novartis…
Novartis charts another 60 layoffs at US corporate outpost
After submitting plans to cut 114 jobs tied to its U.S. headquarters in New Jersey in March, Novartis…
Roche in part-sale of mixed bag lebrikizumab to Dermira
California dermatology biotech Dermira will take on exclusive worldwide rights to IL-13 monoclonal antibody lebrikizumab from Roche, although the Big…
Novartis pens $1.7B atopic disease pact with British biotech
Novartis has tapped up an artificial-intelligence-enabled British biotech for a $1.7 billion biobucks deal to discover new targets…